Renal denervation for congestive heart failure

Abstract

Chronic heart failure remains a condition with a high mortality and symptom burden. Patients have excess sympathetic tone. Pharmacological treatments targeting the sympathetic nervous system and the reninangiotensin-aldosterone system have been shown to have prognostic benefit in systolic heart failure. Renal sympathetic denervation offers the potential to intervene much earlier in the pathway, reducing sympathetic over activity. Pilot data has demonstrated procedural safety in this population. Trials are underway to assess the effect of renal sympathetic denervation in both systolic heart failure and heart failure.